Greenland Mines LtdGRML
Price (close)
$14.89
Market cap
—
P/E
—
Revenue (TTM)
—
Net income
-$21.8M
Dividend yield
—
1-year total return
-37.6%
Net margin
—
Revenue growth
—
Debt / equity
—
What Greenland Mines Ltd does.
Mines”), formerly known as Klotho Neurosciences, Inc., develops essential medicines for the treatment of chronic diseases –
cancer, cardiovascular, and neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio
and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | — | $1.2M | -$707,458 | -$6.2M | -$10.6M |
More on GRML.
- Greenland Mines Ltd summary
- Greenland Mines Ltd financial statements
- Greenland Mines Ltd key metrics
- Greenland Mines Ltd health scores and style box
- Greenland Mines Ltd earnings
- Greenland Mines Ltd dividends
- Greenland Mines Ltd valuation
- Greenland Mines Ltd ownership and insiders
- Greenland Mines Ltd peers
Figures from Greenland Mines Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.